MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Evgen Pharma PLC Company Profile (LON:EVG)

Consensus Ratings for Evgen Pharma PLC (LON:EVG) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: GBX 79

Analysts' Ratings History for Evgen Pharma PLC (LON:EVG)
Show:
DateFirmActionRatingPrice TargetActions
6/1/2016Beaufort SecuritiesReiterated RatingSpeculative BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Northland SecuritiesReiterated RatingBuyGBX 79View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/4/2016Northland Capital PartnersReiterated RatingBuyGBX 79View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Evgen Pharma PLC (LON:EVG)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Evgen Pharma PLC (LON:EVG)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Evgen Pharma PLC (LON:EVG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Evgen Pharma PLC (LON:EVG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/18/2016Clare,BarryInsiderBuy40,000GBX 22£8,800Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Evgen Pharma PLC (LON:EVG)
DateHeadline
06/07/16 08:26 AMSubarachnoid Hemorrhage Global Clinical Trials Review, H1, 2016 - New Market Report
06/01/16 10:11 PMEvgen Pharma : Pleased With "Significant Progress" Since AIM Listing - LONDON (Alliance News) - Clinical stage drug development company Evgen Pharma PLC Tuesday said it has made "significant progress" since its flotation on AIM last year, as it reported a widened loss for its first half. For the year to end-March the company ...
05/31/16 06:07 AMFull Year 2016 Evgen Pharma PLC Earnings Release - Time Not Supplied -
05/09/16 09:29 AMNotification of Preliminary Results - Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its preliminary results for the year ended 31 March 2016 on Tuesday 31 May 2016. A meeting for analysts ...
05/04/16 08:52 AMEVGEN PHARMA - Read Northland Capital Partners's note on EVGEN PHARMA PLC (EVG), out this morning, by visiting https://www.research-tree.com/company/GB00BSVYN304 "The commencement of Evgen’s first Phase II clinical trial is a major milestone for the company.
05/03/16 09:07 AMEvgen Pharma Plc to present at the SHARES Investor Evening in London on 19th May - Stephen Franklin, Chief Executive of Evgen Pharma (EVG) (LSE:EVG) will be giving a briefing at the SHARES Investor Evening on 19th May 2016. It will take place in London at an investor evening being organised by SHARES Magazine; the event is supported by ...
04/28/16 09:18 AMOsteoarthritis Pipeline Market H1 2016 Global Review Report - Evgen Pharma PLC, Galapagos NV, Genequine Biotherapeutics GmbH, GlaxoSmithKline Plc, IntelliCell BioSciences Inc., Jeil Pharmaceutical Co., Ltd., Jenrin Discovery, Inc., K-Stemcell Co., Ltd., Levolta Pharmaceuticals, Inc., Medivir AB, Merck KGaA ...
03/08/16 07:44 AMPipeline of Multiple Sclerosis Market H2 2015 Review Research - Evgen Pharma PLC, Evotec AG, F. Hoffmann-La Roche Ltd., Forward Pharma A/S, Genervon Biopharmaceuticals, LLC, GeNeuro SA, Genmab A/S, Genzyme Corporation, GlaxoSmithKline Plc, GliaCure Inc., Glialogix, Inc., Hansa Medical AB, Hanwha Chemical Corporation ...
03/03/16 07:46 AMBeaufort Securities Breakfast Alert - Tertiary Minerals, Alecto Minerals, Motif Bio and others - Evgen Pharma (LON:EVG, 19.75p) – Speculative Buy Evgen Pharma plc, the clinical stage drug development company focused on the treatment of cancer and neurological conditions, yesterday announced that it had received the required approvals for the ...
03/02/16 07:47 AMApproval of Phase II Clinical Trial in SAH - Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce that it has received the required approvals for the commencement of its Phase II trial of SFX-01 ...
02/12/16 07:17 AMOsteoarthritis H2 2015 market pipeline scrutinized in new research - Evgen Pharma PLC, Galapagos NV, Genequine Biotherapeutics GmbH, GlaxoSmithKline Plc, IMMD Inc., IntelliCell BioSciences Inc., Jeil Pharmaceutical Co., Ltd., Jenrin Discovery, Inc., K-Stemcell Co., Ltd., Levolta Pharmaceuticals, Inc., Medivir AB ...
02/09/16 03:59 PMOsteoarthritis Therapeutics Pipeline Review, H2 2015 - Research and Markets - Plc Ampio Pharmaceuticals, Inc. Amura Holdings Limited Arcarios BV Asahi Kasei Pharma Corp. Asklepios BioPharmaceutical, Inc. Astellas Pharma Inc. Biopharm GmbH Can-Fite BioPharma Ltd. Cara Therapeutics, Inc. Evgen Pharma PLC K-Stemcell Co., Ltd. Levolta ...
01/20/16 06:26 AMCORRECT: DIRECTOR DEALINGS: Evgen Pharma Directors Buy 136,000 Shares - LONDON (Alliance News) - Evgen Pharma PLC Tuesday said a group of directors bought a total of 136,000 shares on Monday in the drug development company. The shares were bought at a price of 22.25 pence per share. Chief Executive Officer Stephen Franklin ...
01/19/16 06:36 AMEvgen Pharma Ord 0.25p - Evgen Pharma, a clinical stage drug development company focused ... The Director now holds 3,754 shares representing 0.00% of the shares in issue.... Evolution Group plc said its investment banking subsidiary Evolution Securities completed a debut retail ...
01/19/16 06:36 AMDIRECTOR DEALINGS: Evgen Pharma Directors Bought 136,000 Shares - LONDON (Alliance News) - Evgen Pharma PLC Tuesday said a group of directors bought a total of 136,000 shares on Monday in the drug development company. The shares were bought at a price of 22.5 pence per share. Chief Executive Officer Stephen Franklin ...
01/19/16 06:36 AMEvgen Pharma PLC (EVG) - Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that, on 18 January 2016, certain Directors purchased an aggregate of 136,000 ordinary shares of 0.25 pence ...
About Evgen Pharma PLC

Evgen Pharma PLC logoEvgen Pharma PLC is a United Kingdom-based clinical-stage drug development company. The Company's lead programs are focused on the treatment of cancers, such as breast and prostate cancer, and neurological conditions, such as subarachnoid hemorrhage. The Company has completed Phase I trials for its development product, SFX-01. It is carrying out preclinical work in relapsing remitting multiple sclerosis. It is also conducting preclinical work for two sulforaphane analogues, SFX-02 and SFX-03 for nuclear respiratory factor (Nrf) 2 activation, anti-cancer activity and genotoxicity. The Company's core technology is Sulforadex, a synthetic and stabilized version of a plant derived compound, sulforaphane, which is an anti-cancer agent. Sulforadex is a complex of sulforaphane and alpha-cyclodextrin in a stable powder, which is in a group of compounds known as antioxidant inflammation modulators (AIMs), affects the activity of transcription factors and thereby influencing gene expression.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: EVG
  • CUSIP:
Key Metrics:
  • Previous Close: $0.22
  • 50 Day Moving Average: $19.19
  • 200 Day Moving Average: $20.62
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $12.25B
  • Current Quarter EPS Consensus Estimate: $4.90 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha